Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival.

Nystrom SJ, Hornberger JC, Varadhachary GR, Hornberger RJ, Gutierrez HR, Henner DW, Becker SH, Amin MB, Walker MG.

Oncotarget. 2012 Jun;3(6):620-8.

2.

A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.

Handorf CR, Kulkarni A, Grenert JP, Weiss LM, Rogers WM, Kim OS, Monzon FA, Halks-Miller M, Anderson GG, Walker MG, Pillai R, Henner WD.

Am J Surg Pathol. 2013 Jul;37(7):1067-75. doi: 10.1097/PAS.0b013e31828309c4.

PMID:
23648464
3.

Cost-effectiveness of gene-expression profiling for tumor-site origin.

Hornberger J, Degtiar I, Gutierrez H, Shewade A, Henner WD, Becker S, Varadhachary G, Raab S.

Value Health. 2013 Jan-Feb;16(1):46-56. doi: 10.1016/j.jval.2012.09.005. Erratum in: Value Health. 2013 Mar-Apr;16(2):452. Varadachary, Gauri [corrected to Varadhachary, Gauri].

4.

Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer.

Kulkarni A, Pillai R, Ezekiel AM, Henner WD, Handorf CR.

Diagn Pathol. 2012 Aug 21;7:110. doi: 10.1186/1746-1596-7-110.

5.

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.

Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA.

J Clin Oncol. 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1.

6.

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Hainsworth JD, Greco FA.

Virchows Arch. 2014 Apr;464(4):393-402. doi: 10.1007/s00428-014-1545-2. Epub 2014 Feb 1. Review.

PMID:
24487792
7.

[Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].

Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M, Huebner G.

Pathologe. 2009 Dec;30 Suppl 2:168-72. doi: 10.1007/s00292-009-1194-4. German.

PMID:
19756615
8.

Comparison of histopathological and gene expression-based typing of cancer of unknown primary.

Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M, Huebner G.

Virchows Arch. 2010 Jan;456(1):23-9. doi: 10.1007/s00428-009-0867-y. Epub 2009 Dec 10.

PMID:
20012089
9.

A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.

Hainsworth JD, Schnabel CA, Erlander MG, Haines DW 3rd, Greco FA.

Clin Colorectal Cancer. 2012 Jun;11(2):112-8. doi: 10.1016/j.clcc.2011.08.001. Epub 2011 Oct 14.

PMID:
22000811
10.

Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD.

Mol Diagn Ther. 2015 Apr;19(2):91-7. doi: 10.1007/s40291-015-0133-8.

PMID:
25758902
11.

Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.

He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q.

World J Gastroenterol. 2013;19(14):2171-8. doi: 10.3748/wjg.v19.i14.2171.

12.

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.

Pentheroudakis G, Greco FA, Pavlidis N.

Cancer Treat Rev. 2009 May;35(3):221-7. doi: 10.1016/j.ctrv.2008.10.003. Epub 2008 Nov 28. Review.

PMID:
19046817
13.

Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications.

Correa ZM, Augsburger JJ.

Graefes Arch Clin Exp Ophthalmol. 2014 Jan;252(1):131-5. doi: 10.1007/s00417-013-2515-0. Epub 2013 Nov 24.

14.

Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial.

Kobashigawa J, Patel J, Azarbal B, Kittleson M, Chang D, Czer L, Daun T, Luu M, Trento A, Cheng R, Esmailian F.

Circ Heart Fail. 2015 May;8(3):557-64. doi: 10.1161/CIRCHEARTFAILURE.114.001658. Epub 2015 Feb 19.

15.

Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.

Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astara G, Macciò A, Serpe R.

J Exp Ther Oncol. 2003 Jul-Aug;3(4):205-19.

PMID:
14567291
16.

Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.

Greco FA.

Curr Treat Options Oncol. 2013 Dec;14(4):634-42. doi: 10.1007/s11864-013-0257-1. Review.

PMID:
23990214
17.

Taxane-based chemotherapy for patients with carcinoma of unknown primary site.

Greco FA, Gray J, Burris HA 3rd, Erland JB, Morrissey LH, Hainsworth JD.

Cancer J. 2001 May-Jun;7(3):203-12.

PMID:
11419028
18.
19.

Overview of various techniques/platforms with critical evaluation of each.

Agwa E, Ma PC.

Curr Treat Options Oncol. 2013 Dec;14(4):623-33. doi: 10.1007/s11864-013-0259-z. Review.

PMID:
24243164
20.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators.

Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6.

PMID:
23746666
Items per page

Supplemental Content

Write to the Help Desk